Sickle cell disease is inherited, lifelong and painful. In India it is concentrated in tribal and central-Indian districts, and it has long been treated as a problem to manage rather than to cure.
In November 2025, Indian scientists announced BIRSA 101: a gene therapy built on a gene-editing protein developed in India, intended as a one-time cure.
It is a genuine scientific achievement, and it has not yet treated a single patient. Both halves of that sentence matter.
What Sickle Cell Disease Is
Red blood cells normally carry oxygen in a soft, round shape that slips easily through the smallest blood vessels. In sickle cell disease, a single change in the gene for haemoglobin makes some cells stiff and curved, like a crescent.
Those cells get stuck. The blockages cause episodes of severe pain, damage to organs over time, anaemia and a shortened life. It is inherited: a child develops the disease when both parents pass on the altered gene.
Carriers, who inherit one copy, are usually healthy and often do not know. That is why screening matters as much as treatment.
Why This Is an Indian Priority
In 2023 the government launched the National Sickle Cell Anaemia Elimination Mission from Shahdol in Madhya Pradesh, with the goal of eliminating the disease as a public health problem by 2047 and screening seven crore people aged 0 to 40 in high-burden districts.
By July 2025, more than 6 crore people had been screened across 17 states. About 2.15 lakh were confirmed to have the disease and about 16.7 lakh were found to be carriers.
The burden falls heavily on tribal communities in states such as Madhya Pradesh, Chhattisgarh, Jharkhand, Gujarat, Odisha and Maharashtra, where access to specialist care is often hardest.
What a Gene Therapy Actually Does
CRISPR is a way of making a precise change at a chosen place in the genome. It is often described as editing text: find the sequence, cut, and let the cell repair the break in a way that changes how a gene behaves.
For sickle cell disease the approach is to take the patient's own blood-forming stem cells, edit them outside the body, and return them. Edited cells then produce healthy haemoglobin.
Because the change is in the patient's own cells, it is given once rather than taken for life. That is what makes it a candidate for a cure rather than a treatment — and also why it is demanding, since the patient needs hospital care of transplant standard.
BIRSA 101
BIRSA 101 was announced on 19 November 2025 by the Union Minister of State for Science and Technology, and developed at the CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) in Delhi.
It is named after Bhagwan Birsa Munda, the tribal leader and freedom fighter, whose 150th birth anniversary was marked that year — a deliberate nod to the communities the disease affects most.
CSIR-IGIB signed a technology transfer agreement with the Serum Institute of India to manufacture it, with clinical trials planned with AIIMS Delhi.
The Part That Is Genuinely India's Own
Most CRISPR work worldwide uses Cas9 from the bacterium Streptococcus pyogenes, known as SpCas9, which carries a thicket of foreign patents and licence fees.
CSIR-IGIB works instead with FnCas9, from a different bacterium, Francisella novicida. Its scientists re-engineered that protein and published the result in Nature Communications in 2024: variants they call enFnCas9, which are reported to match or beat SpCas9 on accuracy while being able to reach far more sites in the genome.
This is the strategic point. An Indian-made editing protein means an Indian therapy is not built on top of someone else's licence, which is a large part of why the cost could fall.
The Cost Question
Approved CRISPR therapies for sickle cell disease abroad are priced at roughly ₹20–25 crore per patient, which puts them beyond any realistic Indian health budget.
Reported estimates for the Indian version are around ₹50 lakh — a reduction of about 97 per cent, and still an enormous sum for the families most affected.
The cost of the editing protein is only part of the bill. Hospital stay, chemotherapy before the infusion, specialised laboratories and follow-up all add to it.
What Has Not Happened Yet
It is worth being exact about where this stands, because announcements of this kind are easily over-read.
The stages between a laboratory result and a patient being cured:
- Gene editor built
- Therapy designed
- Manufacturing partner
- Clinical trials
- Regulatory approval
- Delivery to patients
The first three have happened. The rest have not. Reports put the start of clinical trials in 2026 or 2027, with participants expected from Madhya Pradesh, Chhattisgarh and Jharkhand; the dates in public reporting do not agree, and no results exist yet.
Trials take years, and a therapy that works in a trial still has to be delivered. A one-time cure needs centres that can harvest stem cells, give chemotherapy, infuse edited cells and follow patients afterwards. Those centres are concentrated in big cities, not in the districts where the disease is concentrated.
None of this diminishes the achievement. India has built a gene editor of its own and aimed it at a disease that mainly affects its own people, rather than waiting to license someone else's.
For now, the things that save lives in those districts remain the ordinary ones: screening, counselling before marriage and childbirth, hydroxyurea, pain management and blood transfusion.
A cure that exists is not the same as a cure people can reach. India has now built the first half, in its own laboratories, and named it after a man who died fighting for the communities it is meant to save.
Sources & Further Reading
- PIB: Union Minister launches India's first indigenous CRISPR-based gene therapy for sickle cell disease — Official release on the 19 November 2025 launch of BIRSA 101.
- Nature Communications: PAM-flexible engineered FnCas9 variants for robust and ultra-precise genome editing and diagnostics — The 2024 peer-reviewed paper describing the enFnCas9 variants from CSIR-IGIB.
- Business Standard: Serum Institute and CSIR sign pact to produce affordable gene therapy for sickle cell disease — The technology transfer agreement and cost estimates.
- ORF: BIRSA-101, India's path towards affordable CRISPR therapies — Analysis of the therapy, its trial plans and the delivery challenge.
- PIB: PM launches the National Sickle Cell Anaemia Elimination Mission from Shahdol — The 2023 launch of the mission and its 2047 goal.
- Akashvani News: Six crore screened under the sickle cell mission — July 2025 figures: screenings, confirmed cases and carriers.
- CSIR-IGIB: Gene therapy — The institute's own page on its gene therapy work.